Table 1.
Patients characteristics.
| Characteristic | N (%) | |
|---|---|---|
| All patients | 144 | |
| Sex | ||
| Female | 54 (37.5) | |
| Male | 90 (62.5) | |
| Age (years) | ||
| Median(range) | 53.(45-81) | |
| Year of diagnosis | ||
| 1998-2007 | 17 (11.8) | |
| 2008-2017 | 67 (46.5) | |
| 2018-2021 | 60 (41.7) | |
| Ann Arbor stage | ||
| I | 89 (61.8) | |
| II | 55 (38.2) | |
| HP status | ||
| Negative | 28 (19.4) | |
| Positive | 96 (66.7) | |
| Unknow | 20 (13.9) | |
| Anti-HP therapy | ||
| No | 50 (34.7) | |
| Yes | 94 (65.3) | |
| MALT-IPI | ||
| 0 | 122 (84.7) | |
| 1 | 22 (15.3) | |
| LDH > UNL | ||
| No | 136 (94.4) | |
| Yes | 8 ( 5.6) | |
| Primary lesion | ||
| Multiple | 46 (31.9) | |
| Single | 98 (68.1) | |
| Ki67% | ||
| ≤10 | 99 (68.8) | |
| 11~60 | 20 (13.9) | |
| Unknow | 25 (17.4) | |
| Ectopic chromosome | ||
| No | 36 (25.0) | |
| Unknow | 72 (50.0) | |
| Yes | 36 (25.0) | |
| CD20+ | ||
| Negative | 18 (12.5) | |
| Positive | 84 (58.3) | |
| Unknow | 42 (29.2) | |
| R | ||
| No | 81 (56.2) | |
| Yes | 63 (43.8) | |
| Radiotherapy | ||
| No | 39 (27.1) | |
| Yes | 105 (72.9) | |
| Radiotherapy dose | ||
| 30-35Gy | 83 (57.6) | |
| 30Gy | 6 ( 4.2) | |
| 36-42Gy | 14 ( 9.7) | |
| No | 41 (28.5) | |
| Chemotherapy | ||
| No | 74 (51.4) | |
| Yes | 70 (48.6) | |
| Surgery | ||
| No | 132 (91.7) | |
| Yes | 12 ( 8.3) | |
| First line treatment | ||
| Pharmacotherapy | 39 (27.1) | |
| Radiotherapy | 56 (38.9) | |
| RT+PT | 49 (34.0) | |
MALT-IPI, MALT lymphoma prognostic index; LDH, Lactate dehydrogenase; UNL, Upper normal limit; R, Rituximab; RT+PT, Radiotherapy and Pharmacotherapy.